Literature DB >> 26777876

Clinical updates in adult acute lymphoblastic leukemia.

Omar Al Ustwani1, Neha Gupta2, Hatoon Bakhribah3, Elizabeth Griffiths3, Eunice Wang3, Meir Wetzler3.   

Abstract

Acute lymphoblastic leukemia (ALL) is a clonal disease characterized by B or T lineage. Here we cover the clinical manifestations, pathophysiology and therapy for ALL. Additionally, we will discuss the evidence for minimal residual disease assessment, novel molecular targets and newly developed targeted therapies. The separation of ALL into Philadelphia chromosome positive and recently into Philadelphia-like disease represents the most exciting developments in this disease. Finally, the advent of new immunotherapeutic approaches led us to predict that in few years, ALL therapy might be based heavily on non-chemotherapeutic approaches.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Adolescents and young adults; Chimeric antigen receptors; Minimal residual disease; Monoclonal antibodies; Philadelphia chromosome; Tyrosine kinase inhibitors

Mesh:

Year:  2015        PMID: 26777876     DOI: 10.1016/j.critrevonc.2015.12.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

1.  Family history of any cancer for childhood leukemia patients in Sweden.

Authors:  Xinjun Li; Kristina Sundquist; Jan Sundquist; Asta Försti; Kari Hemminki
Journal:  EJHaem       Date:  2021-05-03

Review 2.  Chimeric antigen receptor-modified T cells strike back.

Authors:  Matthew J Frigault; Marcela V Maus
Journal:  Int Immunol       Date:  2016-03-28       Impact factor: 4.823

Review 3.  [Myelodysplastic syndrome, acute leukemia and stem cell transplantation].

Authors:  M Schmalzing; M Aringer; M Bornhäuser; J Atta
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

Review 4.  P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

Authors:  Stefania Trino; Luciana De Luca; Ilaria Laurenzana; Antonella Caivano; Luigi Del Vecchio; Giovanni Martinelli; Pellegrino Musto
Journal:  Front Pharmacol       Date:  2016-12-16       Impact factor: 5.810

5.  An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells.

Authors:  Min-Wu Chao; Han-Li Huang; Wei-Chun HuangFu; Kai-Cheng Hsu; Yi-Min Liu; Yi-Wen Wu; Chao-Feng Lin; Yi-Lin Chen; Mei-Jung Lai; Hsueh-Yun Lee; Jing-Ping Liou; Che-Ming Teng; Chia-Ron Yang
Journal:  Oncotarget       Date:  2017-04-25

6.  MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.

Authors:  Desheng Kong; Linlin Zhao; Lili Sun; Shengjin Fan; Huibo Li; Yanqiu Zhao; Zhibo Guo; Leilei Lin; Lin Cui; Ke Wang; Wenjia Chen; Yihui Zhang; Jin Zhou; Yinghua Li
Journal:  J Cell Mol Med       Date:  2018-04-19       Impact factor: 5.310

7.  C/EBPβ induces B-cell acute lymphoblastic leukemia and cooperates with BLNK mutations.

Authors:  Morito Kurata; Iichiro Onishi; Tomoko Takahara; Yukari Yamazaki; Sachiko Ishibashi; Ryo Goitsuka; Daisuke Kitamura; Junko Takita; Yasuhide Hayashi; David A Largaesapda; Masanobu Kitagawa; Takuro Nakamura
Journal:  Cancer Sci       Date:  2021-10-23       Impact factor: 6.716

8.  Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.

Authors:  Linlin Zhao; Chengfang Lv; Lili Sun; Qi Li; Yuhuang Wang; Min Wu; Yuying Wang; Zhibo Guo; Sicheng Bian; Desheng Kong; Leilei Lin; Yu Wang; Jin Zhou; Yinghua Li
Journal:  Invest New Drugs       Date:  2021-02-10       Impact factor: 3.850

9.  Vertebral Compression Fractures-The First Manifestations in the Elderly Acute Lymphoblastic Leukemia.

Authors:  Cheng Liu; Cuili Shu
Journal:  Geriatr Orthop Surg Rehabil       Date:  2021-06-22

10.  Depression following graft-versus-host disease in a patient with acute lymphoblastic leukaemia: A case report.

Authors:  Konstantinos Tsamakis; Christoph Mueller; Panagiotis Tsirigotis; Dimitrios Tsiptsios; Charalampos Tsamakis; Emmanouil Charakopoulos; Chistophis Charalampous; Demetrios A Spandidos; Athanasios Douzenis; Charalabos Papageorgiou; Ioannis Liappas; Emmanouil Rizos
Journal:  Mol Clin Oncol       Date:  2019-12-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.